Danish Pharmacovigilance Update, February 2016

09 March 2016

News from the EU

  • SGLT2 (sodium-glucose co-transporter 2) inhibitors and development of life-threatening atypical ketoacidosis in patients with type 2 diabetes, page 2
  • New recommendations to minimise the risk of PML in connection with treatment with natalizumab (Tysabri), page 3
  • EU's list of recommendations on safety signals, page 4

News from the Danish Medicines Agency

  • Special focus on reported adverse reactions to biological medicines and biosimilars, page 5
  • Development in the number of melatonin users younger than 25 years of age from 2007-2015, page 12
  • Beware of interactions between miconazole and warfarin – new, serious ADR reports, page 14

Short news

  • Most recent Direct Healthcare Professional Communications (DHPCs), page 15

Link

Danish Pharmacovigilance Update, February 2016

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.